Biogen Inc Cmn (BIIB) 301.83 $BIIB Ionis Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 10:11 PM

Biogen Inc Cmn (BIIB) 301.83 $BIIB

Ionis Pharmaceuticals (IONS) Stock Surges 36% on Clinical Trial Success
Afrasiab Mian - Zacks Investment Research - Mon Aug 01, 1:04PM CDT
Shares of Ionis Pharmaceuticals (IONS) stock soared over 36% on Monday on news that the company's clinical drug trial for spinal muscular atrophy in infants was successful.
BIIB: 301.83 (+11.90), IONS: 38.01 (+8.82)

Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 5.08% Rise
Comtex SmarTrend(R) - Mon Aug 01, 11:49AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.06 to a high of $307.49. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $290.46 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 301.83 (+11.90)

SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 5.08% Gain
Comtex SmarTrend(R) - Mon Aug 01, 11:47AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.06 to a high of $307.49. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $290.46 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 301.83 (+11.90)

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 67.37 (+0.03), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), PFE: 37.31 (+0.42), SGNT: 21.68 (-0.01), ABBV: 66.94 (+0.71), PRTA: 56.66 (+1.61), NVS: 83.07 (-0.19)

Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
BusinessWire - Mon Aug 01, 6:30AM CDT
---- Biogen Exercises Option to Develop and Commercialize Nusinersen Globally --
BIIB: 301.83 (+11.90), IONS: 38.01 (+8.82)

UCB (UCBJF) Posts 1H16 Results, Reaffirms 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:15AM CDT
UCB (UCBJF) reported results for the first half of 2016.
BIIB: 301.83 (+11.90), AMGN: 174.16 (+2.13), NKTR: 17.76 (+0.47)

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 7:02AM CDT
Amgen (AMGN) once again delivered a "beat and raise" quarter with growth products accounting for more than 50% of product sales.
BIIB: 301.83 (+11.90), INVA: 13.04 (+0.17), AMGN: 174.16 (+2.13), FMS: 45.65 (unch)

Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 6:13AM CDT
Although total revenues were just shy of expectations, Vertex's (VRTX) CF franchise sales improved sequentially.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), INVA: 13.04 (+0.17), ANIP: 61.06 (+0.46)

2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), CELG: 114.69 (+2.50), NVS: 83.07 (-0.19)

5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:36AM CDT
How will drug stocks like AMGN, GSK, VRTX and others, scheduled to report on Jul 27, fare this earnings season?
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), VRTX: 98.20 (+1.20), MDCO: 39.03 (-0.08), AMGN: 174.16 (+2.13), GSK: 45.25 (+0.18), ANIK: 50.64 (+0.72)

Fresh Research Reports For Intel (INTC), AT&T (T) & Others
Sheraz Mian - Zacks Investment Research - Mon Jul 25, 1:23PM CDT
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
BIIB: 301.83 (+11.90), RCI: 44.02 (-0.15), T: 43.18 (-0.11), PHM: 21.44 (+0.26), INTC: 34.85 (-0.01), SYK: 117.02 (+0.74)

Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 8:30AM CDT
Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen
BIIB: 301.83 (+11.90), PFE: 37.31 (+0.42), AMGN: 174.16 (+2.13), BMY: 76.19 (+1.38), SNY: 42.49 (-0.14)

What's in Store for these 5 Drug Stocks in Q2 Earnings?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 7:24AM CDT
Medical stocks are once again expected be among the better performers in Q2. Johnson & Johnson (JNJ) and Biogen have already set the tone with beats and raised outlooks.
MDVN: 64.08 (+0.09), BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), ALDR: 30.79 (-1.31), SGEN: 49.22 (+1.16), NEO: 8.52 (-0.20), EXAS: 18.11 (+0.73)

Q2 Earnings Central Stays Busy, GM Sets New Record
Mark Vickery - ZACKS - Thu Jul 21, 4:07AM CDT
General Motors (GM) posted a record quarterly sales number and reached its first profit in the European market since 2011.
BIIB: 301.83 (+11.90), BX: 26.47 (-0.37), AXP: 64.13 (-0.33), QCOM: 61.85 (-0.73), GM: 31.30 (-0.24), INTC: 34.85 (-0.01), TRV: 116.81 (+0.59), LUV: 37.04 (+0.03)

SB5, An Adalimumab Biosimilar Referencing Humira(R), Accepted for Review by European Medicines Agency
BusinessWire - Sun Jul 17, 8:05PM CDT
--The approval of SB5 could make Biogen the first company to commercialize three anti-TNF biosimilar therapies in Europe
BIIB: 301.83 (+11.90)

Biogen (BIIB) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Jul 15, 8:17AM CDT
Will Tecfidera scrips and sales recover enough to boost Biogen's (BIIB) performance in the second quarter?
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), LLY: 83.18 (+0.29), NVS: 83.07 (-0.19)

Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing
Arpita Dutt - Zacks Investment Research - Wed Jul 13, 2:17PM CDT
Immuno-oncology focused Juno (JUNO) remained in the news with the FDA first placing a clinical hold on a pivotal study and then removing it.
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), CYTR: 0.60 (-0.05), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), JUNO: 30.86 (-0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CATL Opens Europe's Largest Battery Service Hub

A New Era for EV Batteries in Norway Stepping into Oslo's tech realm, CATL's grand opening is not just another corporate ribbon-cutting spree. It's a big splash in Europe's battery pool, boasting the largest NING SERVICE center outside of Asia. Here we are, folks, at the crossroads where the EV market meets the nitty-gritty of practical service. Norway's Electric...

Quantum Sky's Strategic Leadership Overhaul Targets Growth

Executive Shake-Up Aims for Stronger Federal Market Alignment Buckle up, folks—there's some major chess-piecing happening at Quantum Sky. They've just named not one or two, but three executive bigwigs to head up their core business groups. This isn’t just some ceremonial reshuffle. Nah, it’s bigger. They're redefining how they tackle the Department of War, Intel &...

PostalAnnex Lands at Stanford with New Service Hub

PostalAnnex Makes a Strategic Stanford Move It's not every day you see a company nestling into a place like Stanford University. Annex Brands has just opened its latest PostalAnnex location, a stone’s throw from the academic hustle and bustle of the Stanford campus. The geeky vibe of students and professors rushing with deadlines matches well with the efficient service...

Unicycive's Legal Turmoil: Opportunity for Investor Action

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

PhoenixAI and Cloudera's Strategic Partnership Shifts Data Landscape

Time to Embrace Change: PhoenixAI Teams with Cloudera Mention the word 'partnership' in the tech space, and it's often as common as a cup of joe at dawn—but this one truly shakes things up. We're talking about PhoenixAI hitching its wagon to Cloudera's startup circus, a merging of fire and steel in AI-driven database management. With PhoenixAI strutting its stuff on the...

Subaru, Motorq Offer Hardware-Free Fleet Telematics Insights

An Unplugged Move in Fleet Management There's something brewing between Motorq and Subaru that could shake up fleet operations in ways most haven't thought possible yet. We’re talking about cutting those pesky hardware cords and diving straight into a future that's software-driven—and hey, we're all here for it. Direct, Data-Driven Leadership Imagine you're a fleet...

Spotlight on AI-Powered Smart Homes for 2027

Gearing Up for the Connected Home Revolution Ah, the thrill of peering into the future of smart homes! That's what's cookin' as Parks Associates gears up for its annual CONNECTIONS™ Conference slated for May 4-6, 2027. This isn't just another routine pow-wow. Nope, this get-together is about seeing who's leading the pack in transforming our everyday spaces into...

VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...

Brands Must Choose: Cost or Value Leadership?

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

illycaffè's B Corp™ Recertification Reflects Bold Commitment

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...